Dr. Reddy’s Laboratories launches Bupropion tablets in US
DSIJ Intelligence / 03 Sep 2016
Dr. Reddy's Laboratories has launched Bupropion HCl Extended-Release Tablets, USP (SR) in the US market. The company’s Bupropion HCl tablets have already received approval from US Food & Drug Administration (USFDA).
Dr. Reddy's Laboratories has launched Bupropion HCl Extended-Release Tablets, USP (SR) in the US market. The company’s Bupropion HCl tablets have already received approval from US Food & Drug Administration (USFDA). Its Bupropion SR tablets are available in 100 mg, 150 mg and 200 mg in bottle count sizes of 60, 100 and 500.
These tablets are a generic version of Wellbutrin SR (Bupropion HCI) sustained-release tablets, a trademark of GSK group of companies. Wellbutrin SR is an aminoketone antidepressant indicated for the treatment of major depressive disorders (MDDs). The Wellbutrin SR brand and generic brand generated US sales of approximately USD 109.6 million (Rs 730 crore) MAT for the trailing twelve months as per IMS Health.
The share price of Dr. Reddy’s Laboratories increased by 0.79 per cent on bourses; and closed at Rs 3122.65 on Friday.
Dr. Reddy's Laboratories operates in three segments viz. global generics; pharmaceutical services and Active Ingredients (PSAI); and proprietary products. The company operates in markets across USA, India, Russia & Commonwealth of Independent States (CIS) countries and Europe.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.